While Amgen Inc. recorded an 18 percent increase in revenues for 2005, the company's stock slid Thursday when it failed to release much-anticipated data for its colorectal cancer drug panitumumab. (BioWorld Today)

As it continues to launch its first cardiovascular product, NitroMed Inc. raised gross proceeds of $62.5 million in a private placement of common stock. (BioWorld Today)

Despite a market cap of close to $3 billion and a 58 percent increase in Erbitux revenues in 2005, ImClone Systems Inc. is exploring strategic options that could include the sale of the company. (BioWorld Today)